Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.
All News
Article
Article
The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021.
Article
During Day 2 there were great sessions devoted to RA, spondylarthritis, fatigue and more. Here are some of my highlights from Day 2.
Meral K. El Ramahi, MD
Tweet
⭐️Deucravacitnib = oral TYK2i w/ downstream inhibitory effects on IL23, IL12 & type I IFN pathways ⭐️Recent studies (POETYK PSO-1/2) show that it outperforms Otezla per PASI75 ⭐️OP0227 shows it is also efficacious for active PsA vs PBO w/ no serious AEs #EULAR2021 @Rheumnow https://t.co/qA1NsLzQsF
Fecal Transplantation as Potential PsA Treatment: Dr. Eric Dein ( @ejdein1) #EULAR2021
https://t.co/ItYAEIJZSW https://t.co/uHnY9cWLEj
"What we really need in SpA/PsA is personalized medicine in order to choose the best drug MOA for our patients." Dr. Laura Coates addressing paradox of choice in treatment options. I remain hopeful for better biomarkers for future precision medicine approach. #EULAR2021 @RheumNow https://t.co/nIDksfTe7h
Q-DAPSA for Measuring Disease Activity in PsA by Dr. Rachel Tate ( @uptoTate) #EULAR2021
https://t.co/fbi3Kbd2GS https://t.co/afRnle1EJK
Aurelie Najm
Tweet
DISCOVER 1&2: whole blood transcriptome in PsA: dysregulation of immune cell profiles vs. Ctrl
Guselkumab modulates genes expr towards normalization of immune cell composition. Would be interesting to look at STissue
signatures too 🧐 @StefanSiebert1 #POS0195 @Rheumnow #EULAR2021 https://t.co/7WChCP3U6W
Novel target (IL23-i; Guselkumab) in treating TNF-IR #psoriaticarthritis. Dr Coates presented results from Phase III COSMOS. 44.4% of GUS-treated vs 19.8% Placebo-tx achieved ACR20 response at Wk24 (p<0.001). Well tolerated and No major safety #EULAR2021 #OP0230 @RheumNow https://t.co/EuGaacSuxF
#OP0227 #TYK2 inhibitor deucravacitinib showed good efficacy in #PsA patients vs. placebo in phase 2 16weeks
Primary endpoint ACR20
12mg: 62.7%
6mg: 52.9%
PLC: 31.8%
+ well tolarated: no serious adverse events
#EULAR2021 @RheumNow https://t.co/6SFqWd79db
Prospective analysis #OP0220 showed that PsA pt age, dz duration and activity level at tx initiation have ⬇️ with TNFi over the past 20 years. TNFi retention rates have ⬇️ while remission rates have ⬆️ (notably those in 1st yr tx) #EULAR2021 @RheumNow https://t.co/gnKRfvbHPQ https://t.co/PRunGIxMwx
Janet Pope
Tweet
Ever wonder why one drug works in a pt & not another? Study of bio markers in PsA from RCT of #upadacitinib vs #adalimumab shows diff pathways affected by each drug & some overlap too @RheumNow #EULAR2021 @eular_org OP0030 https://t.co/WifrVOIMkW
UPSTREAM results #OP0223 suggest that the newly developed and preliminary validated MSKUS PsA dz activity and damage scores could be used in observational and controlled trials.
#EULAR2021 @RheumNow https://t.co/Tw7OWyMcgX https://t.co/WiT0yGwVqK
Does Guselkumab (IL23-i) modulate gene expression in #PsA? Dr Siebert analysed samples from DISCOVER RCTs & reported normalisation of⬆️regulated genes (e.g. Neutrophil,monocyte) and ⬇️regulated (B-,T- and NK cells) signatures by GUS post-therapy #EULAR2021 #POS0195 @RheumNow https://t.co/2qtpxrrwkF
GUS causes ⬇️ in serum collagen C1M (marker of joint response), C3M, C4M, C6M. Pts achieving ACR20 at week 24 had greater C1M reduction than non-responder. Abstract #POS1036 #EULAR2021 @RheumNow https://t.co/4JqbaMexuR https://t.co/gXltKn6qIc
In biologic-naïve PsA pts - 2 yr data, GUS improved skin & joint symptoms, physical function, & radiographic progression. Safety comparable to 6mo/1yr data, similar between Q4W & Q8W dosing, & consistent w/ PsO trials. Poster #POS1027 #EULAR2021 @RheumNow https://t.co/nlcjOX7cBq https://t.co/NWqDTwfb4u
#EULAR2021 PROs in Spa and PSA: Dr. Rachel Tate ( @uptoTate )
Dr. Rachel Tate reviews two abstracts - OP0051 and OP0049 - presented at the virtual EULAR 2021 meeting.
https://t.co/sUXTXDXrFh https://t.co/tQZktnlUXj
